Reuters logo
BRIEF-U.S. FDA approves supplemental New Drug Applications for three Type 2 diabetes medicines
January 4, 2017 / 10:36 PM / 9 months ago

BRIEF-U.S. FDA approves supplemental New Drug Applications for three Type 2 diabetes medicines

Jan 4 (Reuters) - Eli Lilly And Co

* U.S. FDA approves supplemental new drug applications to include landmark data in product labels for synjardy (empagliflozin/metformin hydrochloride), synjardy xr (empagliflozin/metformin hydrochloride extended-release) and glyxambi (empagliflozin/linag

* Eli Lilly and Co - data show empagliflozin reduced risk for cardiovascular death compared with placebo when added to standard of care type 2 diabetes

* Eli Lilly and Co - data have been added to “clinical studies” sections of prescribing information for synjardy, synjardy xr, glyxambi tablets Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below